Screener
Polaryx Therapeutics, Inc. PLYX Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
| Line item | As of / December 31, 2025 | As of / December 31, 2024 |
|---|---|---|
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value, 40,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Common stock: $0.0001 par value; 560,000,000 shares authorized; 47,343,297 and 41,151,571 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5 | 4 |
| Additional paid-in capital | 104,195 | 95,358 |
| Accumulated deficit | (99,635) | (90,650) |
| Total stockholders’ equity | 4,565 | 4,712 |
| Total liabilities and stockholders’ equity | $5,170 | $5,001 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s common stock par value per share?
- Polaryx Therapeutics, Inc. (PLYX) reported common stock par value per share of $0.00 in Q4 2025.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Polaryx Therapeutics, Inc.'s common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude